Science we believe in.
Companies we’ve built.

Automera is focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation.

Automera leverages its unique understanding of autophagy and access to quantum chemistry to enhance its drug development programs. Automera’s AUTAC platform which comprises a proprietary warhead-linker library has broad potential across multiple therapeutic areas, with neurodegenerative disease being the initial lead program.